Type 1 Diabetes Trial, Recruiting NCT06547970 Sponsor: University of Baghdad Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT06547970
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 16 years or older who can speak and read Arabic
  • People who have been diagnosed with Type 1 diabetes for at least 6 months
  • People whose blood sugar is not well controlled, meaning their HbA1c blood test result is 7% or higher, and/or their fasting blood sugar level is above 130 mg/dl
  • People who have been on the same diabetes treatment plan for the last 3 months
  • People (or their parents, if applicable) who agree to take part in the study

Who may not be able to join:

  • People who have hearing, speech, or thinking/understanding difficulties that would make it hard to answer questions or take part in education sessions
  • People who have certain other health conditions alongside their diabetes, such as asthma, thyroid problems, adrenal gland disorders, coeliac disease, or significant kidney problems
  • People who are currently taking corticosteroid medications (a type of steroid medicine)
  • People whose insulin treatment plan needs to be changed, or whose insulin dose needs to be increased by more than 20%
  • People with conditions that affect how their red blood cells work or turn over, such as certain types of anaemia, G6PD deficiency, a recent blood transfusion, use of medicines that stimulate red blood cell production, end-stage kidney disease, or pregnancy
  • People who do not wish to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ali Lateef Jasim, PhD, Baghdad University

Phone: 7901735013

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Baghdad
Registry
ClinicalTrials.gov
Start date
1 February 2024
Est. completion
1 September 2024

Where this trial is recruiting

Iraq

Primary endpoints

Glycated hemoglobin A1c (%) (HbA1c); The Quality of Life Scale (QoL)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov